STAT+: A spending frenzy on obesity drugs
STAT
APRIL 24, 2024
Want to stay on top of the science and politics driving biotech today? Today we have some developments about Novo Nordisk’s insulin business, a side of the company that people don’t really talk about anymore, and some news about their GLP-1 business, a side that people can’t stop talking about.
Let's personalize your content